DECOMPRESSIONE PORTOSISTEMICA INTRAEPATICA TRANSGIUGULARE PER IL TRATTAMENTO DELLE COMPLICANZE SECONDARIE A IPERTENSIONE PORTALE IN PAZIENTI CON INSUFFICIENZA EPATICA TERMINALE

Translated title of the contribution: Transjugular intrahepatic portosystemic shunt for the treatment of portal hypertension related complications in patients with end-stage liver disease

F. A. Bartoli, A. B. Zajko, L. A. Aldrighetti, P. D. Orons, N. Jabbour, G. D. Dodd, A. G. Tzakis, J. J. Fung

Research output: Contribution to journalArticlepeer-review

Abstract

Sixty-eight cirrhotic patients with portal hypertension underwent transjugular intrahepatic portosystemic shunt (TIPS). The mean follow-up after TIPS was 299 ± 243 days. Using the Child-Pugh score, 11 patients were class A, 39 class B and 18 class C. Indications for TIPS were acute or recurrent variceal bleeding in 67 patients and intractable ascites in the remaining patient. Following TIPS, the mean portosystemic gradient (PSG) dropped from 25 ± 5 to 10 ± 4 mmHg. Non procedure-related bleeding complications occurred. Hepatic encephalopathy developed or worsened in 23/68 patients (34%). The incidence of hepatic encephalopathy was greater in patients achieving a reduction in PSG ≥ 50% of the pre-TIPS value. Recurrent hemorrhage occurred in 15 patients (22%); only in 7 of them (46%) it was due to gastric varices (2 cases) or portal hypertensive gastropathy (5 cases). The incidence of recurrent bleeding was lower in patients with a final PSG

Translated title of the contributionTransjugular intrahepatic portosystemic shunt for the treatment of portal hypertension related complications in patients with end-stage liver disease
Original languageItalian
Pages (from-to)335-341
Number of pages7
JournalChirurgia
Volume8
Issue number9-10
Publication statusPublished - 1995

ASJC Scopus subject areas

  • Surgery

Fingerprint Dive into the research topics of 'Transjugular intrahepatic portosystemic shunt for the treatment of portal hypertension related complications in patients with end-stage liver disease'. Together they form a unique fingerprint.

Cite this